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The clinical benefit conferred by vascular endothelial
growth factors (VEGF)-targeted therapies is variable,
and tumors from treated patients eventually reinitiate
growth. Here, we identify a glycosylation-dependent
pathway that compensates for the absence of
cognate ligand and preserves angiogenesis in
response to VEGF blockade. Remodeling of the
endothelial cell (EC) surface glycome selectively
regulated binding of galectin-1 (Gal1), which upon
recognition of complex N-glycans on VEGFR2,
activated VEGF-like signaling. Vessels within anti-
VEGF-sensitive tumors exhibited high levels of
a2-6-linkedsialic acid,whichpreventedGal1binding.
In contrast, anti-VEGF refractory tumors secreted
increased Gal1 and their associated vasculature dis-
playedglycosylationpatterns that facilitatedGal1-EC
interactions. Interruption of b1-6GlcNAc branching in
ECs or silencing of tumor-derived Gal1 converted
refractory into anti-VEGF-sensitive tumors, whereas
elimination of a2-6-linked sialic acid conferred resis-
tance to anti-VEGF. Disruption of the Gal1-N-glycan
axis promoted vascular remodeling, immune cell
influx and tumor growth inhibition. Thus, targeting
glycosylation-dependent lectin-receptor interactions
may increase the efficacy of anti-VEGF treatment.INTRODUCTION
Genetic and pharmacological disruption of vascular signaling
pathways have provided unequivocal evidence that abnormal744 Cell 156, 744–758, February 13, 2014 ª2014 Elsevier Inc.angiogenesis is a hallmark feature of cancer (Chung and Ferrara,
2011; Potente et al., 2011). Vascular endothelial growth factors
(VEGFs) play central roles in this process through activation of
VEGF receptor tyrosine kinases (RTKs), including VEGFR1
(Flt-1), VEGFR2 (KDR/Flk-1), and VEGFR3 (Flt-4) on endothelial
cells (ECs) (Chung and Ferrara, 2011). Blockade of VEGF-A
signaling with bevacizumab, a humanized anti-VEGF mono-
clonal antibody (mAb), or with RTK inhibitors has improved pro-
gression-free survival and, in some indications overall survival,
across several types of cancers, including metastatic colorectal
cancer, non-small-cell lung cancer, metastatic breast cancer,
renal cell carcinoma, and hepatocarcinoma (Ellis and Hicklin,
2008). However, the clinical benefit conferred by these therapies
is variable, and tumors from treated patients eventually reinitiate
growth (Ebos et al., 2009).
It has been suggested that induction of compensatory angio-
genic pathways may contribute to limit the efficacy of anti-VEGF
treatment. This proposition is supported by preclinical data
showing the release of alternative proangiogenic signals and
the mobilization of angio-competent bone marrow-derived
myeloid cells by anti-VEGF refractory tumors (Bergers and Ha-
nahan, 2008). Future antiangiogenic therapies should capitalize
on an improved understanding of these compensatory pathways
as well as the identification of hallmark signatures that can delin-
eate sensitivity to anti-VEGF treatment.
Programmed remodeling of cell-surface glycans through the
sequential action of glycosyltransferases and glycosidases reg-
ulates a variety of physiologic and pathologic processes (Oht-
subo and Marth, 2006; Hart and Copeland, 2010). Glycosylation
controls EC biology by modulating Notch receptor signaling
(Benedito et al., 2009), sustaining EC survival (Kitazume et al.,
2010), regulating vascular permeability (Xu et al., 2011), and con-
necting blood and lymphatic vessels (Fu et al., 2008). Likewise,
changes in the cellular glycome could alter vascular processes
by displaying or masking ligands for endogenous lectins, which
translate glycan-containing information into functional cellular
responses (Rabinovich and Croci, 2012). Galectin-1 (Gal1), a
member of a conserved family of animal lectins, promotes tumor
progression through mechanisms leading to tumor-immune
escape and metastasis (Rubinstein et al., 2004; Banh et al.,
2011; Dalotto-Moreno et al., 2013). Interestingly, Gal1 is regu-
lated by hypoxia (Le et al., 2005; Croci et al., 2012) and controls
EC signaling (Hsieh et al., 2008), VEGFR trafficking (D’Haene
et al., 2013), and tumor angiogenesis (Thijssen et al., 2006,
2010; Mathieu et al., 2012; Laderach et al., 2013). Here, we eval-
uated the hypothesis that Gal1 association with glycosylated EC
receptors might link tumor hypoxia to angiogenic compensatory
programs in response to VEGF blockade.
RESULTS
Context-Dependent Regulation of the EC Glycome
Controls Gal1 Binding and Angiogenesis
We first examined the ‘‘glycosylation signature’’ of human ECs at
baseline and following exposure to physiologically relevant stim-
uli. We used a panel of lectins that recognize specific glycan
structures, including those that are relevant for Gal1 binding.
Gal1 recognizes multiple galactose-b1-4-N-acetylglucosamine
(LacNAc) units, which are present on the branches of N- or
O-linked glycans and are created by the concerted action of spe-
cific glycosyltransferases. This includes the N-acetylglucosami-
nyltransferase 5 (MGAT5), an enzyme that generates b1-6-N-
acetylglucosamine (b1-6GlcNAc)-branched complexN-glycans,
which are the preferred intermediates for LacNAc extension (Fig-
ure 1A). Under resting conditions, primary human umbilical vein
ECs (HUVEC) showed considerable expression of L-phyto-
hemagglutinin (L-PHA)-reactive MGAT5-modified N-glycans
and Lycopersicon esculentum lectin (LEL)-reactive poly-LacNAc
ligands, which increased significantly following exposure to
immunosuppressive cytokines (IL-10 or TGF-b1) or to proangio-
genic FGF2 (Figures 1B and 1C). In contrast, ECs exposed to
proinflammatory TH1 (IFN-g) or TH17 (IL-17) cytokines showed
significantly lower L-PHA reactivity (Figure 1C). As a2-6 sialyl-
transferase (ST6GAL1) may modify LacNAc ligands and block
Gal1 signaling (Toscano et al., 2007), we then examined binding
of Sambucus nigra agglutinin (SNA), a lectin that recognizes a2-
6-linked sialic acid (SA). Stimulation of ECs with FGF2 or a com-
bination of IL-10 and TGF-b1 led to reduction of SNA-reactive
glyco-epitopes, as compared to resting, IL-17- or IFN-g-treated
ECs (Figures 1B and 1C), suggesting that pro- or anti-inflamma-
tory signals may either mask or unmask Gal1-specific binding
sites. In contrast, ECs showed similar binding profiles for the
Maackia amurensis agglutinin (MAL II), which recognizes a2-3
SA linkages, regardless of the stimulus used (Figures 1B and 1C).
Exposure of Gal1-specific glyco-epitopes may also be regu-
lated by the core-2 b1-6-N-acetylglucosaminyltransferase 1
(C2GNT1), which acts on asialo-galactose-b1-3-N-acetylgalac-
tosamine core 1 O-glycans to synthesize the core 2 branching
structure (Figure 1A). Exposure of HUVEC to FGF2, IL-10, or
TGF-b1 resulted in modest increase of peanut agglutinin (PNA)-
reactive asialo-core-1 O-glycans, compared to cells exposed
to IFN-g or IL-17 (Figures 1B and 1C). However, we observed
no significant binding of the a-N-acetyl-galactosamine-reactiveHelix pomatia agglutinin (HPA) (Figure 1B). Moreover, exposure
to VEGF-A resulted in no significant changes in the EC glycophe-
notype (Figure 1C). Thus, immunosuppressive stimuli favor a
Gal1-permissive glycophenotype on ECs, while proinflammatory
signals reduce expression of these glyco-epitopes. Similar re-
sults were observed using the mouse EC line EOMA (data not
shown).
To determine the contribution of EC surface glycosylation to
Gal1 function, we examined Gal1 binding to ECs under different
experimental conditions. Gal1 bound to ECs in a dose- and car-
bohydrate-dependent fashion (Figure 1D). Accordingly, a Gal1
mutant lacking carbohydrate-binding activity (Gal1N46D) did not
bind to ECs at any of the concentrations tested (Figure 1D).While
Gal1 binding was almost completely abrogated by swainsonine,
an inhibitor ofN-glycan biosynthesis, benzyl-a-GalNAc, an inhib-
itor of O-glycan elongation, was only partially inhibitory (Fig-
ure 1D), suggesting the essential contribution of N-glycans to
Gal1 signaling. Moreover, decrease of N-glycan branching
through siRNA-mediated silencing of MGAT5 almost completely
eliminated Gal1 binding, whereas inhibition of core 2 O-glycan
elongation through C2GNT1 silencing had no effect (Figure 1E
and Figures S1A, and S1B available online). Consistent with
changes in glycosylation, Gal1 binding was higher in ECs
exposed to immunosuppressive stimuli compared to cells
sensing proinflammatory cytokines (Figure 1F).
Because hypoxia fuels activation of angiogenic rescue pro-
grams (Potente et al., 2011), we askedwhether hypoxicmicroen-
vironments could influence the EC glycan profile. Hypoxia
increased the amounts of b1-6GlcNAc-branched N-glycans
and poly-LacNAc structures, reduced a2-6 sialylation, and
induced slight changes in asialo-core-1 O-glycans in compari-
son to normoxia (Figure 1G). These results were substantiated
by glycan nanoprofiling, which documented an increase in the
relative abundance of neutral N-glycans and a decrease in tri-
and tetra-sialylated N-glycans on ECs exposed to hypoxia (Fig-
ures 1H and S1C). Accordingly, we found higher binding of Gal1
to ECs cultured under hypoxic conditions (Figure 1I).
We then analyzed the contribution of N- and O-glycans to the
proangiogenic functions displayed by Gal1 and VEGF-A. Addi-
tion of lactose or decrease of N-glycan branching through
MGAT5 silencing or swainsonine treatment almost completely
prevented EC proliferation, migration, and tube formation
induced by Gal1, while silencing C2GNT1 had no effect. Accord-
ingly, exposure to Gal1N46D mutant had no impact on EC
responses (Figures 1J and S1D–S1F). In contrast, the proangio-
genic effects of VEGF-A were preserved regardless of the
absence or presence of complex N- or O-glycan branching (Fig-
ures 1J and S1D–S1E). Thus, unlike VEGF-A, Gal1 delivers
proangiogenic signals through a glycosylation-dependent
pathway involving context-dependent remodeling of complex
N-glycans.
Glycosylation-Dependent Binding of Gal1 to ECsMimics
VEGF-A Function
To integrate the Gal1-N-glycan axis into canonical angiogenic
circuits, we studied themolecular basis of Gal1-receptor interac-
tions. Screening for changes in the phosphorylation status of a
spectrum of growth factor RTKs and signaling nodes revealedCell 156, 744–758, February 13, 2014 ª2014 Elsevier Inc. 745
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that VEGFR2 was the only tested RTK that became phosphory-
lated following treatment of ECs with Gal1 (Figures 2A and S2A).
This phosphorylation pattern was detected at 15 min (Figure 2A)
and was sustained after 60 min of exposure to this lectin (data
not shown). In addition, Gal1 increased the phosphorylation of
Akt (Thr308), Akt (Ser473), and Erk1/2, recapitulating the phos-
phorylation pattern elicited by VEGF-A (Figures 2A, S2B, and
S2C). Silencing VEGFR2 almost completely prevented Akt and
Erk1/2 phosphorylation induced by either Gal1 or VEGF-A (Fig-
ure 2B and S2D) and abrogated Gal1-induced EC migration
and tube formation (Figures 2C, 2D, S2E, and S2F). In contrast,
blockade of VEGFR1, VEGFR3, or integrins avb3 or a5b1 had no
effect on Gal1-induced EC functions (Figure 2D). Likewise,
silencing neuropilin-1 (NRP-1), a recognized Gal1-binding part-
ner (Hsieh et al., 2008), had no significant impact on Gal1 func-
tion (Figure 2C, S2D, and S2E). Because of the autocrine effects
of VEGF signaling (Lee et al., 2007), we examined whether Gal1
signaling proceeded in the absence of VEGF-A. Consistent with
lack of effect of Gal1 on VEGF-A secretion (Figure S2G), inhibi-
tion of intracellular or extracellular VEGF-A had no influence on
Gal1 effects (Figures 2C, 2D, S2E, S2F, and S2H). Similarly,
FGF2 blockade did not alter Gal1 activity (Figure S2F).
As branching of complex N-glycans may fine-tune the
threshold for growth factor signaling (Dennis et al., 2009; Song
et al., 2010), we further investigated whether MGAT5-modified
glycans can modulate sensitivity of VEGFR2 to its canonical
ligand VEGF-A. Targeting MGAT5 selectively eliminated respon-
siveness to Gal1, but it had no impact on VEGF signaling (Fig-
ure 2B). In contrast, blockade of core 2 O-glycan elongation
had no effect on Gal1 or VEGF-A signaling (data not shown).
Hence, rather than altering VEGF-A signaling, Gal1 directly
co-opts the VEGFR2 pathway through binding to complex
N-glycans. Coimmunoprecipitation experiments with HUVEC
treated with Gal1 in the absence or presence of PNGase F or
following transfection with MGAT5 or C2GNT1 siRNA revealed
that Gal1 associated with VEGFR2 through N-glycosylation-
dependent mechanisms (Figure 2E). These interactions were
confirmed by Fo¨ster resonance energy transfer (FRET) analysis
of 594-Gal1 binding to fully-glycosylated 488-VEGFR2, which re-
vealed a bimodal behavior and a dissociation constant (Kd)
within the low micromolar range (Figures 2F and S2I). Titration
of the Gal1-VEGFR2 complex with lactose confirmed the glycan
dependence of these interactions showing a considerable in-Figure 1. Remodeling of the EC Glycome Controls Gal1 Function
(A) Schematic representation of N- and O-glycan biosynthesis.
(B) Glycophenotype of resting HUVEC detected with biotinylated lectins (filled
experiments.
(C) Glycophenotype of HUVEC treated with different stimuli (rMFI [relative mean fl
Presented as ratio relative to resting conditions (dotted line) (mean ± SEM, n = 4
(D and E) Binding of 488-Gal1 or 488-Gal1N46D to HUVEC treated with inhibitors
(F) Binding of 488-Gal1 to HUVEC treated with different stimuli (mean ± SEM, n
(G) Glycophenotype of HUVEC cultured in hypoxia (gray) or normoxia (green) dete
Representative of five experiments.
(H) Glycan nanoprofiling of HUVEC exposed to normoxia or hypoxia (mean ± SE
(I) Binding of 488-Gal1 to HUVEC exposed to hypoxia or normoxia (mean ± SEM
(J) Tube formation of HUVEC transfected or not with specific siRNA and incubate
inhibitors (mean ± SEM, n = 5, **p < 0.01 versus control, yp < 0.05 versus Gal1).
See also Figure S1.crease of 488-VEGFR2 fluorescence, which displayed a
hyperbolic behavior and revealed an apparent Kd of 250 mM
(Figure 2F), similar to that calculated for the Gal1-lactose
complex (Lo´pez-Lucendo et al., 2004). Immunoprecipitation
followed by lectin blotting revealed considerably lower
amounts of a2-6-linked SA in VEGFR2 compared to VEGFR1,
consistent with the preferential association of Gal1 with VEGFR2
(Figure 2G).
VEGFR2 is organized into seven extracellular immunoglobulin
(Ig)-like folds and contains 18 putative N-linked glycosylation
sites. While Ig-2 and -3 mediate VEGF-A binding, Ig-4 to -6 con-
trol receptor dimerization and Ig-7 stabilizes dimer formation
(Olsson et al., 2006). To identify which domains are responsible
for Gal1 binding, we prepared a series of human VEGFR2
mutants that are devoid of N-glycosylation sites in each of the
seven Ig-like domains (Figure S2J). The HA-tagged wild-type
(WT) and VEGFR2 mutants were stably expressed in HEK293T
cells, showing comparable total and cell-surface expression
(Figure S2K). Using anti-HA-conjugated 633-fluorescent beads,
we immunoprecipitated VEGFR2 variants and examined binding
of 488-Gal1 to immunoprecipitates. Flow cytometry of double-
positive beads revealed that mutations in N-glycosylation sites
of Ig-3 (N245Q, N318Q), Ig-4 (N374Q, N395Q), and Ig-7
(N675Q, N704Q, N721Q) partially prevented Gal1 binding (Fig-
ure 2H), suggesting major contributions of these domains to
glycan-dependent recognition of this lectin. Binding of Gal1 re-
sulted in N-glycan-dependent segregation of VEGFR2 to mem-
brane patches, indicating rearrangement of signaling clusters
on the EC surface (Figure 2I). Moreover, this lectin-modulated
cell-surface residency of VEGFR2 and its internalization, which
occurred with slower kinetics than those triggered by VEGF-A
(Figures 2J, S2L, and S2M). Thus, Gal1 co-opts the VEGFR2
signaling pathway through binding to nonsialylated N-glycans
on this RTK.
Differential Glycosylation of Tumor-Associated
Vasculature Delineates Sensitivity to Anti-VEGF
Treatment
To investigate whether the Gal1-N-glycan axis preserves
vascularization in anti-VEGF refractory tumors, we evaluated
changes in the ‘‘glycosylation signature’’ of ECs associated
with tumors that are known to be sensitive (B16-F0 melanoma
and CT26 colon carcinoma) or refractory (LLC1 Lewis lung) or with PE-conjugated streptavidin alone (open). Representative of eight
uorescence intensity] = (MFI with lectin – MFI without lectin)/MFI without lectin).
; *p < 0.05, **p < 0.01 versus resting).
(D) or transfected with specific siRNA (E) (mean ± SEM, n = 4; **p < 0.01).
= 4; *p < 0.05, **p < 0.01 versus resting).
cted with biotinylated lectins or with PE-conjugated streptavidin alone (open).
M, n = 3; *p < 0.05).
, n = 5; **p < 0.01).
d with Gal1 (1 mM), Gal1N46D (3 mM) and/or VEGF-A (20 ng/ml) with or without
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Figure 2. Glycosylation-Dependent Binding of Gal1 to ECs Mimics VEGF-A Function
(A) Phospho-RTK signaling array of HUVEC exposed to medium, VEGF-A, or Gal1. Right: quantification of pixel intensity (mean ± SEM, n = 4; *p < 0.05, **p < 0.01
versus control).
(B) Immunoblot of phosphorylated and total VEGFR2, Akt and Erk1/2 in HUVEC transfected or not with specific siRNA and treated with Gal1 (1 mM) or VEGF-A
(20 ng/ml). Representative of three experiments.
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carcinoma and R1.1 T cell lymphoma) to anti-VEGF treatment
(Shojaei et al., 2007). We confirmed marked inhibition of tumor
growth and reduced vascular supply in B16-F0- and CT26-sen-
sitive tumors implanted into syngeneic mice and treated with
the anti-VEGF mAb, whereas growth and vascularization of
LLC1 and R1.1 refractory tumors were only transiently and
poorly inhibited (Figures 3A and 3B). In vitro, conditioned media
(CM) from LLC1 and R1.1 cells that were previously exposed to
hypoxia induced consistent changes in the glycan repertoire of
ECs, as reflected by diminished display of a2-6-linked SA,
greater exposure of b1-6-branched N-glycans and increased
frequency of poly-LacNAc-extended glycans, compared to
ECs exposed to CM from tumor cells cultured in normoxia (Fig-
ure 3C). Accordingly, we found higher binding of Gal1 to ECs
exposed to CM from LLC1 tumor cells cultured in hypoxic con-
ditions (Figure S3A). Induction of a ‘‘Gal1-permisive’’ glycan
repertoire was a feature of anti-VEGF refractory but not sensi-
tive tumors, as B16-F0 and CT26 cells were unable to promote
changes in the EC glycophenotype when exposed to hypoxia
(Figure 3C). This differential responses could not be attributed
to selective upregulation of proangiogenic factors (FGF2,
TGF-b1, or VEGF-A) by different tumor cell lines (Figure S3B).
Thus, hypoxia acts as a major driving force that instructs
anti-VEGF refractory but not sensitive tumors to selectively
alter the EC glycan profile.
To evaluate changes in the glycophenotype of tumor-asso-
ciated vessels in vivo, mice were implanted with sensitive or
refractory tumors and treated with anti-VEGF or control mAb
when tumors reached 100 mm3. Four and 7 days after anti-
VEGF treatment, vessels within refractory tumors showed
reduced a2-6 sialylation and higher b1-6 N-glycan branching
(Figure 3D). Refractoriness was also associated with higher
secretion of Gal1, but not other proangiogenic galectins
by tumor cells (Figures 3F and S3C). In contrast, vessels
within sensitive tumors showed no significant alterations of
the EC glycophenotype and no changes in Gal1 secretion in
response to VEGF blockade (Figures 3E and 3F). Thus, anti-
VEGF refractory tumors selectively respond to VEGF blockade
by upregulating Gal1 expression and modulating the EC-asso-
ciated glycan profile. Based on these findings, we sought to
analyze Gal1 expression in tumors obtained from a Kras-
driven genetically engineered mouse model of pancreatic
ductal adenocarcinoma (PDAC), which responds to anti-
VEGF treatment with no changes in progression-free or overall
survival (Singh et al., 2010). We found higher Gal1 expression(C and D) Tube formation of HUVEC transfected or not with specific siRNA (C) or
SEM, n = 4; **p < 0.01; ***p < 0.001).
(E) Coimmunoprecipitation followed by immunoblot of Gal1 and VEGFR2 of HUV
with specific siRNA or treatment with PNGase F. Input, whole-cell lysate. Repres
(F) Binding of 594-Gal1 to 488-rhVEGFR2 followed by FRET. Left: fluorescence
presence of 594-Gal1 titrated with lactose. Representative of three experiments
(G) Immunoprecipitaton of VEGFR1 and VEGFR2 followed by lectin blotting. Two
(H) Binding of Gal1 to immunoprecipitated KDR-HA mutants lacking N-glycosyla
WT-KDR).
(I) Confocal microscopy of VEGFR2 segregation in HUVEC transfected or not with
representative [right], n = 4; **p < 0.01, ***p < 0.001).
(J) Flow cytometry of VEGFR2 in nonpermeabilized HUVEC treated with VEGF-A
See also Figure S2.in anti-VEGF-treated versus anti-ragweed-treated PDAC tu-
mors (Figure S3D), thus substantiating the robust upregulation
of this lectin in tumors with limited responses to anti-VEGF
treatment.
Tumor Depletion of Gal1 Confers Sensitivity
to Anti-VEGF Treatment
To explore the relative contribution of Gal1 to anti-VEGF sensi-
tivity, syngeneic mice were implanted with LLC1 or R1.1 tumors
expressing shRNA-Gal1 constructs and treated with anti-VEGF
mAb when tumors reached 100 mm3. Silencing Gal1 increased
sensitivity to anti-VEGF treatment in both LLC1 and R1.1 tumors,
as evidenced by diminished tumor burden (Figures 4A and S4A)
and vascularization (Figure 4B) following injection of anti-VEGF
mAb. This effect was not due to differences in in vitro prolifera-
tion between WT and knockdown tumors (Figure S4B). Tumor
growth inhibition was not further enhanced when Gal1 knock-
down LLC1 cells were inoculated into syngeneic Gal1-deficient
(Lgals1/) mice (Figure 4C), suggesting no substantial contribu-
tion of host-derived Gal1 to this effect. On the other hand, target-
ing Gal1 in anti-VEGF-sensitive B16-F0 tumors induced only a
slight improvement of the therapeutic benefits of VEGF blockade
(Figures 4D, 4E, and S4C). These changes were not associated
with undesired off-target effects as Gal1, but not other relevant
tumor galectins, was altered following Gal1 shRNA transduction
(Figures S4A and S4D). Thus, targeting Gal1 in the tumor micro-
environment may help to increase the efficacy of anti-VEGF
treatment.
Reprogramming of EC Glycosylation Modulates Tumor
Sensitivity to Anti-VEGF
To investigate the relevance of EC glycosylation in anti-VEGF
compensatory programs, we implanted anti-VEGF refractory
or sensitive tumors into glycosyltransferase-deficient mice.
Given the selective upregulation of b1-6GlcNAc-branched
N-glycans in vessels associated with anti-VEGF refractory
tumors (Figure 3D), we sought to elucidate the contribution
of this pathway to the compensatory angiogenic phenotype.
Mice lacking MGAT5 were implanted with the LLC1 refractory
tumor and treated with anti-VEGF or control mAb. Lack of
PHA reactivity confirmed the absence of b1-6GlcNAc-
branched oligosaccharides in tumor-associated ECs from
Mgat5/ mice (Figure 5A). Anti-VEGF treatment in Mgat5/
mice led to marked inhibition of tumor growth and
vascularization compared to their WT counterparts (Figuresincubated with relevant blocking Ab (D) and treated or not with Gal1 (mean ±
EC treated with or without Gal1 (left) or treated with Gal1 following transfection
entative of three experiments.
intensity (518 nm). Right: fluorescence intensity of 0.5 mM 488-VEGFR2 in the
.
representative of three experiments are shown.
tion sites in Ig-like domains (mean ± SEM, n = 4; *p < 0.05, **p < 0.01 versus
specific siRNA and treated with Gal1 or Gal1 plus lactose (mean ± SEM [left] or
, Gal1 or VEGF-A plus Gal1 (mean ± SEM, n = 4; **p < 0.01).
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Figure 3. Differential Glycosylation of Tumor-Associated Vasculature Delineates Sensitivity to Anti-VEGF Treatment
(A and B) Tumor growth (A) and percentage of tumor-associated ECs (B) in mice inoculated with the indicated tumors and treated with anti-VEGF (5 mg/kg) or
control mAb (mean ± SEM, n = 4, six animals per group; *p < 0.05, **p < 0.01).
(legend continued on next page)
750 Cell 156, 744–758, February 13, 2014 ª2014 Elsevier Inc.
DC
B
Days after inoculation
0 10 20 30
0
500
1000
1500
2000
Tu
m
or
 v
ol
um
e 
(m
m
3 )
Control
B16-F0 sh-scr + anti-VEGF
B16-F0 shGal1.1 + anti-VEGF
** **
**
0 5 10 15 20 25
0
500
1000
1500
2000
2500
Control
R1.1 sh-scr + anti-VEGF
R1.1 shGal1.1 + anti-VEGF
**
Days after inoculation
Tu
m
or
 v
ol
um
e 
(m
m
3 )
*
0
500
1000
1500
2000
2500
0 5 10 15 20 25
Control
LLC-1 sh-scr + anti-VEGF
LLC-1 shGal1.1 + anti-VEGF
Days after inoculation
Tu
m
or
 v
ol
um
e 
(m
m
3 )
***
*
0 5 10 15 20 25
0
500
1000
1500
2000
2500
3000
Control
LLC1 sh-scr + anti-VEGF
LLC1 shGal1.1 + anti-VEGF
Lgals1-/-
mice
E
C
s 
(%
) 
5
10
15
20
Control
anti-VEGF
**
LLC-1 WT
sh
Ga
l1.
1
**
sh
-sc
r
5
10
15
20
 E
C
s 
(%
) 
R1.1 WT
sh
Ga
l1.
1
**
Control
anti-VEGF
**
sh
-sc
r
 E
C
s 
(%
) 
5
10
15
20
B16-F0 WT
sh
Ga
l1.
1
Control
anti-VEGF
sh
-sc
r
A
Tu
m
or
 v
ol
um
e 
(m
m
3 )
Days after inoculation
E
**
**
LLC1
B16-F0 
R1.1
LLC1 R1.1
LLC1 
B16-F0 
** **
Figure 4. Tumor Depletion of Gal1 Confers Sensitivity to Anti-VEGF Treatment
(A and B) Tumor growth (A) and percentage of tumor-associated ECs (B) in B6 mice inoculated with LLC1 or R1.1 tumors transduced with Gal1-specific shRNA
(shGal1.1) or sh-scr and treated with anti-VEGF or control mAb (mean ± SEM, n = 4 with six animals per group; *p < 0.05; **p < 0.01).
(C) Tumor growth in Lgals1/B6mice inoculatedwith LLC1 tumors transducedwith shGal1.1 or sh-scr and treated with anti-VEGF or control mAb (mean ±SEM,
n = 3 with six animals per group; **p < 0.01).
(D, E) Tumor growth (D) and percentage of tumor-associated ECs (E) in B6 mice inoculated with B16-F0 tumors transduced with shGal1.1 or sh-scr and treated
with anti-VEGF or control mAb (mean ± SEM, n = 4 with six animals per group; **p < 0.01).
See also Figure S4.5B and 5C). Thus, lack of b1-6GlcNAc-branched N-glycans in
tumor-associated vessels converted otherwise refractory into
anti-VEGF-sensitive tumors.
Because a2-6-linked SA is highly represented in the vascu-
lature of anti-VEGF-sensitive tumors, we hypothesized that
lack of a2-6 sialylation may render tumors insensitive to anti-
VEGF treatment. Mice lacking ST6GAL1 were implanted with
the B16-F0-sensitive tumor and treated with anti-VEGF or con-
trol mAb. Lack of SNA reactivity confirmed the absence of a2-
6-linked SA in tumor-associated vessels (Figure 5D). Loss of
a2-6-sialylation in tumor-associated vasculature conferred
reduced sensitivity to anti-VEGF treatment, as shown by
increased tumor growth and formation of a highly dense tumor
vascular network (Figures 5E and 5F). This phenotype could be
rescued when St6gal1/ mice were challenged with Gal1-(C) Glycophenotype of ECs exposed to serum-free conditioned media from the in
n = 4; *p < 0.05, **p < 0.01, ***p < 0.001).
(D and E) Glycophenotype of vessels associated to LLC1 (D) or B16-F0 (E) tumors
group *p < 0.05, **p < 0.01).
(F) ELISA of Gal1 secretion by different tumors in response to anti-VEGF treatme
See also Figure S3.deficient B16 tumors and further treated with anti-VEGF mAb
(Figure 5G), suggesting that loss of a2-6-linked SA may
enhance vascular signaling by unmasking Gal1-specific
ligands. Furthermore, this compensatory program was sup-
pressed when St6gal1/ mice were implanted with B16
tumors and further treated with anti-VEGF mAb in the pres-
ence of the RTK inhibitor axitinib, which preferentially sup-
presses VEGFRs signaling (Figure 5G). However, no changes
in tumor growth or vascularization were observed in response
to VEGF blockade when a sensitive tumor was inoculated into
Mgat5/ mice or when a refractory tumor was grown in
St6gal1/ mice (data not shown). Thus, reprogramming of
the EC glycome, leading to disruption of Gal1-specific ligands,
may contribute to circumvent refractoriness to anti-VEGF
treatment.dicated tumor cells previously cultured in normoxia or hypoxia (mean ± SEM,
in response to anti-VEGF treatment in vivo (mean ± SEM, n = 4; six animals per
nt (mean ± SEM, n = 4; *p < 0.05, **p < 0.01).
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Figure 5. Reprogramming of EC Glycosyla-
tion Modulates Tumor Sensitivity to Anti-
VEGF
(A) Flow cytometry of L-PHA binding to ECs
associated to LLC1 tumors inoculated into WT or
Mgat5/ mice (day 16). Representative of four
experiments with six animals per group.
(B and C) Tumor growth (B) and percentage of
tumor-associated ECs (C) inMgat5/ or WT mice
inoculated with LLC1 tumors and treated with anti-
VEGF or control mAb (5 mg/kg) (mean ± SEM,
n = 4 with six animals per group; **p < 0.01, ***p <
0.001).
(D) Flow cytometry of SNA binding to ECs asso-
ciated to B16-F0 tumors inoculated into WT or
St6gal1/ mice (day 16). Representative of four
experiments with six animals per group.
(E and F) Tumor growth (E) and percentage of
tumor-associated ECs (F) in St6gal1/ or WT
mice inoculated with B16-F0 tumors and treated
with anti-VEGF or control mAb (mean ± SEM, n = 4
with six animals per group; **p < 0.01, ***p < 0.001).
(G) Tumor growth in St6gal1/ mice inoculated
with B16-F0 tumors and treated with anti-VEGF
mAborwithanti-VEGFmAbplusaxitinib (30mg/kg)
or inoculated with B16-F0 tumors transduced with
Gal1-specific shRNA (shGal1.1) and treated with
anti-VEGF mAb (mean ± SEM, n = 3 with six ani-
mals per group; **p < 0.01).Targeting the Gal1-N-Glycan Axis Overcomes
Refractoriness to Anti-VEGF Treatment and Promotes
Vascular Remodeling
In the quest for a therapeutic agent capable of defeating anti-
VEGF refractoriness, we evaluated the therapeutic effects of a
function-blocking Gal1 mAb (F8.G7) selected by its ability to
neutralize Gal1, but not other galectins (Croci et al., 2012). This
mAb specifically prevented tube formation and EC migration
induced by Gal1, but not VEGF-A (Figures 6A and S5A), and in-
hibited Gal1-induced VEGFR2 phosphorylation to levels compa-
rable to those attained by MGAT5 silencing (Figure 6B).
Administration of F8.G7 mAb (10 mg/kg) successfully circum-
vented anti-VEGF refractoriness displayed by LLC1 and R1.1 tu-
mors, asevidencedby reduced tumorgrowthandvascularization
at day 7 following combined treatment (Figures 6C and 6D). On
the other hand, Ab-mediated Gal1 blockade slightly enhanced
the therapeutic benefit of anti-VEGF in the sensitive B16 tumors
(Figure 6E). Remarkably, single administration of F8.G7 mAb
afforded sustained inhibition of tumor growth and vascularization
inmice bearing refractory or sensitive tumors (Figures 6C–6E and
S5B). Of note, the amounts of secreted Gal1 varied considerably752 Cell 156, 744–758, February 13, 2014 ª2014 Elsevier Inc.among different inoculated tumor types
but dropped substantially following
administration of the F8.G7 mAb (Fig-
ure 6F). Thus, Gal1 blockade limits refrac-
toriness to anti-VEGF treatment.
As previous studies indicate that
vascular-targeted strategies should
combine mechanisms of vessel pruning
with the capacity to promote normaliza-tion of the remaining tumor vasculature (Carmeliet and Jain,
2011),we investigatedwhetherGal1blockadeprovidedawindow
of opportunity for tumor vessel normalization. Notably, mAb-
mediated Gal1 blockade resulted in substantial remodeling of
the vasculature of B16 tumors at days 4–5 posttreatment (Figures
6G–6J). While tumors treated with the isotype control mAb dis-
played a disorganized and heterogeneous vascular architecture,
tumor vasculature frommice treated with F8.G7 mAb resembled
normal vascular networkswith regard to vessel diameter and dis-
tribution (Figure 6G). Moreover, vessels from F8.G7 mAb-treated
tumors showed greater coverage by pericytes (Figure 6H), which
displayed a more mature phenotype, as revealed by higher
expression of a-smooth muscle actin (a-SMA) and lower expres-
sion of regulator of G protein signaling 5 (RGS5) and platelet-
derived growth factor receptor (PDGFR)-b (Figure 6I). Supporting
these findings, administration of F8.G7 mAb markedly alleviated
tumor hypoxia as shown by reduced formation of pimonidazole
adducts (Figure 6J). However, Gal1 blockade failed to promote
vessel normalization later after treatment (data not shown), sug-
gesting the transient nature of this effect. Remarkably, we
observed a similar vascular remodeling effect following
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administration of F8.G7 mAb into WT mice bearing LLC1 tumors
or when tumors were implanted into Mgat5/ mice in the
absence of Gal1 blockade (Figures 6K and 6L). Thus, disruption
of the Gal1-N-glycan axis counteracts the aberrant nature of the
tumor vasculature not only by attenuating angiogenesis, but
also by modulating vessel morphology early after treatment.
Disruption of Gal1-N-Glycan Interactions Affords
Therapeutic Benefits through the Control of Both
Vascular and Immune Compartments
Because vessel normalization increases the access of immune
cells into the tumor (Carmeliet and Jain, 2011) and Gal1 sup-
presses antitumor immunity (Rubinstein et al., 2004), we sought
to dissect the relative contribution of immune and vascular com-
partments to tumor growth suppression induced by Gal1
blockade. Whereas administration of F8.G7 mAb to tumor-
bearing immunocompetentmice resulted inmarkedly decreased
tumor burden (Figures 6C–6E), treatment of immunodeficient
B6.Rag1–/– mice yielded only a partial antitumor effect (Fig-
ure S6A), suggesting the contribution of the immune system to
the therapeutic effects of F8.G7 mAb. Accordingly, administra-
tion of F8.G7 mAb in mice bearing B16-F0 or LLC1 tumors stim-
ulated T cell proliferation, enhanced IFN-g and IL-17 secretion,
and blunted IL-10 production by tumor-draining lymph node
(TDLN) cells (Figures 7A–7G). Moreover, an increase in the num-
ber of TDLN and tumor-infiltrating CD8+ T cells was detected in
F8.G7 mAb- versus control-treated mice (Figure 7H–7J). To
elucidate the contribution of N-glycan branching to this effect,
we inoculated LLC1 tumors into Mgat5/ mice. Notably,
MGAT5 deficiency mirrored the immunostimulatory effects of
Gal1 blockade, as revealed by cytokine production and fre-
quency of TDLN and tumor-infiltrating immune cells in tumor-
bearing Mgat5/ versus WT mice (Figures 7K–7Q).
To examine whether heightened immunity was, at least in part,
mediated by increased access of immune cells due to vessel
normalization, T cells obtained from tumor-bearing mice were
labeled with CFSE and transferred into mice bearing the same tu-
mor but treatedwith F8.G7 or isotype controlmAb. A greater num-
ber of T cells reached the tumor, but not the spleen, in mice
receiving F8.G7 mAb as compared to those treated with control
isotype (Figure 7R), suggesting increased influx of immune cellsFigure 6. Targeting the Gal1-N-Glycan Axis Overcomes Anti-VEGF Ref
(A) Tube formation of HUVEC treated with Gal1 or VEGF-A with or without anti-G
(B) Immunoblot of VEGFR2 phosphorylation in HUVEC treated with Gal1 with
Representative of three experiments.
(C–E) Growth of LLC1 (C, left), R1.1 (D) and B16-F0 (E, left) and microvessel dens
and/or F8.G7 or isotype control mAb (mean ± SEM, n = 4 with six animals per gr
(F) ELISA of Gal1 secretion (day 16) by tumors inoculated in B6 mice and treated
group; ***p < 0.001).
(G) Confocal microscopy of lectin (GLS-1B4)-perfused vessels in sized-matched
isotype control mAb. Vessel diameter (right).
(H) Confocal microscopy of lectin-perfused vessels (green) and anti-a-SMA Ab
4–5 days with F8.G7 or isotype control mAb. Right, percentage of tumor vessels
(I) Confocal microscopy of RGS5, desmin, a-SMA and PDGFR-b in pericytes as
4-5 days with F8.G7 or isotype control mAb. Quantification (left) and representat
(J) Confocal microscopy of B16-F0 sized-matched tumors stained with Hypoxip
(K and L) Confocal microscopy of CD31 (K) and lectin-perfused vessels (L, green) a
with F8.G7 or isotype control mAb or inoculated into Mgat5/ mice.
Mean ± SEM, n = 4 with six mice per group (G, H, I, K, and L); *p < 0.05, **p < 0.
754 Cell 156, 744–758, February 13, 2014 ª2014 Elsevier Inc.subsequent to vessel remodeling. This effectwas confirmedusing
fluorescent beads injected into F8.G7mAb-treated tumor-bearing
WT mice and control-treated tumor-bearing Mgat5/ mice (Fig-
ures S6B and S6C), thus validating the contribution of complex
N-glycans to the vascular remodelingeffect. These results empha-
size the dual and interrelated effects of blockingGal1-N-glycan in-
teractions, which contribute to restrain tumor growth by attenu-
atingaberrant vascularnetworksandpotentiating tumor immunity.
DISCUSSION
Although underappreciated for many years, recent studies have
illuminated the essential contribution of lectin-glycan recognition
systems to a variety of biological processes (Rabinovich and
Croci, 2012). In this study, we highlight the contribution of the EC
glycome to vascular function, integrate the Ga1-N-glycan axis
into canonical angiogenic pathways, and validate a therapeutic
target to surmount anti-VEGF compensatory programs. In addi-
tion, our findings underscore the intimate connections between
vascular and immune cell programs operating in tumorigenesis.
Multivalent interactions between endogenous lectins and gly-
cans have been shown to function as tuners that, in response to
canonical ligands, control cellular responses by adjusting thresh-
olds of cellular signaling (Dennis et al., 2009). However, the high
avidity of these interactions (Sacchettini et al., 2001), the remark-
able changesdisplayedby thecellular glycome inphysiologic and
pathologic settings (Varki et al., 2009) and thepronouncedpheno-
types observed in mice lacking components of the glycosylation
machinery (Ohtsubo andMarth, 2006), suggest that endogenous
lectins and glycansmight act beyond their tuning function to pro-
vide hierarchical ‘‘on-and-off’’ input information that directly acti-
vates receptor signaling. Our study shows that direct association
of Gal1 with complex N-glycans on VEGFR2 Ig3, Ig4, and Ig7 do-
mains may substitute for the absence of VEGF-A to promote EC
signaling and preserve the angiogenic phenotype. Although
Gal1 could eventually bind other glycosylated receptors, its pref-
erential association with VEGFR2 may reflect differences in a2-6
sialylation, N-glycan number and branching and/or protein
conformation among individual EC glycoproteins. Tumor-associ-
ated stimuli including hypoxia and immunosuppression fuel Gal1
signaling by increasing the availability of nonsialylated complexractoriness and Promotes Vascular Remodeling
al1 (F8.G7) or isotype control mAb (mean ± SEM, n = 4; **p < 0.01).
or without F8.G7 or isotype control mAb or transfected with MGAT5 siRNA.
ity (C and E, right) of tumors inoculated in B6 mice and treated with anti-VEGF
oup; *p < 0.05, **p < 0.01, ***p < 0.001).
with F8.G7 or isotype control mAb (mean ± SEM, n = 4 with five animals per
B16-F0 tumors inoculated in B6 mice and treated for 4–5 days with F8.G7 or
(red) in sized-matched B16-F0 tumors inoculated in B6 mice and treated for
showing pericyte coverage.
sociated to vessels of B16-F0 tumors inoculated into B6 mice and treated for
ive images (right) are shown.
robe-1. Representative of four experiments.
nd anti-a-SMA Ab (L, red) in LLC1 tumors inoculated into WTmice and treated
01. See also Figure S5.
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N-glycans, whereas proinflammatory signals limit exposure of
Gal1 ligands. In this regard, tumor necrosis factor, a major proin-
flammatory cytokine, can upregulate expression of ST6GAL1 as
well as other glycosyltransferases responsible for creating selec-
tin ligands during inflammatory responses (Garcia-Vallejo et al.,
2006; Willhauck-Fleckenstein et al., 2010), thus emphasizing the
versatility of the EC glycome and its adaptability to cellular phys-
iology. Interestingly, although Gal1-glycan interactions may pro-
long EC surface residency of VEGFR2 and amplify responses to
VEGF-A, our data show that receptor trafficking and signaling
may also proceed in the absence of VEGF-A, highlighting the
contribution of lectin-glycan recognition to ligand-independent
RTK activation. In this regard, previous studies emphasized the
relevance of N-glycosylation in the signaling capacity of RTKs
including epidermal growth factor receptor (EGFR), ErbB2, and
ErbB3 (Yokoe et al., 2007; Contessa et al., 2008).
Although approved therapies targeting VEGF have offered sig-
nificant clinical benefit by improving progression-free and overall
survival, some patients experienced decreased benefit over
time, suggesting the contribution of compensatory pathways
that preserve angiogenesis in VEGF-targeted therapies (Ebos
et al., 2009). Although some preclinical reports have yielded con-
flicting results (Fischer et al., 2007; Bais et al., 2010), vessel prun-
ing induced by VEGF or VEGFR blockade has been shown to
aggravate hypoxia, resulting in the upregulation of alternative
proangiogenic signals including FGFs, hepatocyte growth fac-
tor/c-Met, placental growth factor, Bv8, and IL-17 (Bergers and
Hanahan, 2008; Shojaei et al., 2010; Chung et al., 2013). Here,
we identified a glycosylation-based circuit, mediated by Gal1-
VEGFR2 interactions, that links tumor hypoxia to vascular
signaling in anti-VEGF refractory tumors. Remarkably, a ‘‘Gal1-
permissive’’ glycophenotype was evident on anti-VEGF refrac-
tory, but not sensitive vessels, in response to hypoxia or VEGF
blockade. However, hypoxia not only favored the exposure of
Gal1-specific ligands, but alsopromotedGal1 expression through
mechanisms involving NF-kB-activation (Croci et al., 2012).
Hence, rather than the upregulation of a single proangiogenic fac-
tor, the Gal1-N-glycan axis emerges as a synchronized program
that is connected with VEGFR2 signaling and bolsters tumor
immunosuppressive networks. Although previous studies sug-
gested that VEGFR2 needs to be internalized into early endo-
somes to signal angiogenesis (Lanahan et al., 2010), recent find-
ings showed that receptor internalization is not required for
upstream signaling to proceed, but it is necessary for activating
distal kinases (Gourlaouen et al., 2013). We found that Gal1 pro-
moted VEGFR2 internalization with a slower kinetics than VEGF-
A, although it triggered full activation of signaling programs.Figure 7. Disruption of Gal1-N-Glycan Interactions Controls Both Vasc
(A–G) Proliferation (A) and ELISA of IFN-g (B and E), IL-17 (C and F), and IL-10 (D an
F8.G7 or isotype control mAb.
(H and I) Flow cytometry of IFN-g-producing CD8 T cells in TDLN frommice inocu
(J) Confocal microscopy of tumor-infiltrating CD8 T cells in mice inoculated with
(K–O) ELISA of IFN-g (K), IL-17 (L), and IL-10 (M), and flow cytometry (N and O) of
inoculated with LLC1.
(P and Q) Confocal microscopy of tumor-infiltrating CD8 T cells (P) and F4/80+ m
(R) Flow cytometry of CFSE+ transferred T cells reaching the tumor or spleen.
Data are the mean ± SEM (A-N, P,Q) or are representative (J left, O, P left, R) of n =
also Figure S6.
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and Gal8, can also promote angiogenesis (Nangia-Makker et al.,
2000; Markowska et al., 2011, Delgado et al., 2011), only Gal1
was upregulated in response to VEGF blockade, suggesting
that the spatiotemporal regulation of individual galectins, their
selective modulation by hypoxia and the repertoire of glycan
structures displayed by tumor vessels, together dictate the
contribution of individual lectins to angiogenic compensatory
programs. In this regard, we found that MGAT5 deficiency
increased the efficacy of anti-VEGF treatment, as interruption
of b1-6GlcNAc branching prevented Gal1 binding to ECs.
Although secreted MGAT5 may also act on heparan sulfate to
promote the release of FGF2 through a glycan-independent
pathway (Saito et al., 2002), thismechanism is unlikely to operate
in our system as FGF2 inhibition did not alter the proangiogenic
effect of Gal1, angiogenesis did not occur in the absence of Gal1
and treatment with swainsonine recapitulated the effect of
MGAT5 silencing. Moreover, our findings provide an alternative
explanation, based on the modulation of vascular and immune
compartments, for the reduced tumor growth observed in
Mgat5/ mice (Granovsky et al., 2000). Conversely, ST6GAL1
ablation abrogated sensitivity to anti-VEGF treatment, suggest-
ing a major role for a2-6-linked SA in modulating vascularization.
This effect was associated with interruption of Gal1-N-glycan
signaling via VEGFR2, as it was prevented by Gal1 silencing or
by administration of axitinib, an RTK inhibitor which preferentially
perturbs VEGFRs signaling. Whether activation of the Gal1-N-
glycan axis contributes to limit the efficacy of VEGF-targeted
therapies in human clinical settings remains to be explored.
In this study we document the effects of a neutralizing Gal1-
specific mAb that prevented compensatory angiogenesis in
anti-VEGF refractory tumors. This therapeutic response did not
involve undesired off-target effects, as F8.G7 mAb did not bind
to other galectins (Croci et al., 2012), was active at relatively
low concentrations (5–10 mg/kg) and phenocopied the conse-
quences of MGAT5 deficiency. Similar to other antiangiogenic
agents, mAb-mediated Gal1 blockade not only suppressed
tumor vascular supply, but also induced transient vessel normal-
ization as reflected by increased pericyte coverage, alleviation of
tumor hypoxia, influx of T cells into the tumor, and subsequent
amplification of immune responses. These results underline
the dual and interconnected effects of vascular and immune
compartments in the context of Gal1 blockade. Importantly,
despite the preferential association of Gal1 with VEGFR2,
blocking Gal1 would not be equivalent to targeting VEGFR2 as
Gal1 could potentially interact with other EC glycosylated
receptors and could also modulate tumor growth throughular and Immune Compartments
dG) by TDLN cells frommice inoculated with B16-F0 or LLC1 and treated with
lated with B16-F0 (H) or LLC1 (I) and treated with F8.G7 or isotype control mAb.
B16-F0 and treated with F8.G7 or isotype control mAb.
IFN-g-producing CD4 (N) or CD8 (O) T cells in TDLN fromMgat5/ or WT mice
acrophages (Q) in Mgat5/ or WT mice inoculated with LLC1.
4 experiments with six mice per group. *p < 0.05, **p < 0.01, ***p < 0.001. See
vascular-independent immune-related mechanisms (Banh et al.,
2011). In this regard, resistance to RTK inhibitors has also been
described in preclinical models (Shojaei et al., 2010), posing the
challenge of tailoring targeted therapies based on the identifica-
tion of individual compensatory programs. Finally, given its im-
munostimulatory effects, targeting the Gal1-N-glycan axis may
also complement immunotherapeutic modalities aimed at
releasing the brakes of tumor immunity, including those involving
CTLA-4 or PD-1/PD-L1 blockade (Coussens et al., 2013).
In conclusion, we identified a glycosylation-based circuit that
links tumor hypoxia, VEGFR2 signaling and compensatory angio-
genesis in the context of VEGF blockade. These findings may
have broader implications in other clinical settings involving dys-
regulated angiogenesis including age-relatedmacular degenera-
tion, diabetes retinopathy, and cardiovascular diseases.
EXPERIMENTAL PROCEDURES
Mice
Lgals1/ mice were provided by F. Poirier, Mgat5–/– mice were provided by
J. Dennis and St6gal1–/– mice were provided by J. Paulson. Mice were bred
at the animal facility of IBYME according to NIH guidelines. Protocols were
approved by the institutional review board.
Glycophenotyping
Cells were incubated with biotinylated lectins (Vector) or 488-labeled Gal1 as
described (Toscano et al., 2007).
Angiogenesis Assays
ECs transfected with MGAT5, C2GNT1 or scr siRNA were exposed to VEGF-A
or Gal1 with or without lactose, anti-VEGFR1 (AP-MAB0702), anti-VEGFR3
(AB89501), mAb (from Abcam) or anti-VEGF-A (MAB293), anti-VEGFR2
(AF357), anti-aVb3 (MAB3050), anti-a5 (AF1864), anti-b1 (MAB17781) integrin
mAb or isotype control IgG1k (all from R&D) or anti-Gal1 (F8.G7) mAb. Cells
were processed for proliferation, migration, and tube formation as described
(Croci et al., 2012). Tumor-associated ECs were identified by flow cytometry
using 647-conjugated anti-CD34 (RAM34; eBioscience) and FITC-conjugated
anti-CD45 (J33; Immunotech). Microvessel density reflected the number of
CD31+ microvessels present in 10 mm2.
Tumor Models
Wild-typeorGal1 knockdownB16-F0, LLC1, andR1.1 (2.5 or 53105 cells)were
s.c. inoculated into 6- to 8-week old WT, Mgat5–/–, St6gal1–/–, Lgals1/, or
Rag1–/–B6mice. CT26 (53 105) cells were injected into BALB/cmice.When tu-
mors reached 100mm3, mice were inoculated i.p. with anti-VEGF (B20-4.1.1; 5
or 10 mg/kg) and/or anti-Gal1 (F8.G7; 5, 10 or 15 mg/kg) mAb or control mAb
twice weekly. Axitinib (30 mg/kg; Sigma) was administered every 2 days by
oral gavage. Mice were sacrificed when tumors reached a volume greater
than 2.5 cm3. Two weeks after tumor inoculation, TDLN cells (5 3 105/ well)
were restimulated ex vivo for 72 hr with tumor lysates and analyzed for prolifer-
ation and cytokine production as described (Rubinstein et al., 2004).
Statistical Analysis
Prism software (GraphPad) was used for statistical analysis. Student’s t test
was used for unpaired data. Two-way ANOVA and Dunnett’s or Tukey post-
tests were used for multiple comparisons. p values of 0.05 or less were consid-
ered significant.
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